Media stories about Teligent (NASDAQ:TLGT) have trended positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teligent earned a daily sentiment score of 0.37 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.135907766633 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Teligent (TLGT) traded down $0.03 during trading on Wednesday, hitting $2.54. The stock had a trading volume of 448,568 shares, compared to its average volume of 488,878. The stock has a market capitalization of $139.37, a price-to-earnings ratio of -11.77 and a beta of 1.13. The company has a debt-to-equity ratio of 2.23, a quick ratio of 2.71 and a current ratio of 3.28. Teligent has a 1 year low of $2.51 and a 1 year high of $9.54.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Teligent from a “sell” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity cut their price objective on shares of Teligent from $4.00 to $3.50 and set a “hold” rating for the company in a report on Friday, March 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. Teligent presently has an average rating of “Hold” and a consensus target price of $6.83.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.